Pancreatic cancer is feeling the heat.
| Autor: | Maru SY; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Convergence Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg Kimmel Immunology Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; The Skip Viragh Center for Clinical and Translational Research, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Jaffee EM; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ejaffee@jhmi.edu.; Convergence Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg Kimmel Immunology Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; The Skip Viragh Center for Clinical and Translational Research, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Oct 28; Vol. 12 (10). Date of Electronic Publication: 2024 Oct 28. |
| DOI: | 10.1136/jitc-2024-010124 |
| Abstrakt: | Pancreatic adenocarcinoma (PDAC) is considered an immunologically 'cold' tumor that fails to attract or support effector T cells. Most PDACs are resistant to immune checkpoint blockade due to the complex signaling pathways that exist within its tumor microenvironment. Recent advances in genomic and proteomic technology advances are finally uncovering the complex inflammatory cellular and intercellular signals that require modulation and reprogramming. The goal is to 'turn up the heat' on PDACs with combination immunotherapies that incorporate T cell activating agents and immune modulatory agents, and successfully eradicate tumors. Here, we discuss progress and promising new research that is moving the field toward this goal. Competing Interests: Competing interests: EMJ reports other support from Abmeta and Adventris, personal fees from Dragonfly, Neuvogen, CPRIT, Surge Tx, Mestag, Medical Home Group, HDTbio, and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. EMJ is the Dana and Albert 'Cubby' Broccoli Professor of Oncology. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|